🔴 Milestone Pharmaceuticals is trading 5% down; no company-specific catalyst identified

Milestone Pharmaceuticals is trading 5.01% lower at $0.82, with no company-specific explanation identified for the October 1 decline.

• The latest identified company news came September 24, when the company reported enrolling its first Canadian participant in a Phase 3 trial.
• Healthcare shares were weak, with reporting citing pressure from sharply higher Treasury yields; available evidence does not establish a direct link to the decline.